Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

VBI VACCINES INC.

(VBIV)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
0.7058 USD   -3.20%
09/29VBI Vaccines Starts Phase 1 Study On Multivalent Coronavirus Vaccine Candidate VBI-2901
MT
09/29VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901
BU
09/29Vbi Vaccines Inc/bc : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Earnings Flash (VBIV) VBI VACCINES Posts Q2 Revenue $346,000

08/08/2022 | 08:02am EDT


© MT Newswires 2022
All news about VBI VACCINES INC.
09/29VBI Vaccines Starts Phase 1 Study On Multivalent Coronavirus Vaccine Candidate VBI-2901
MT
09/29VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine C..
BU
09/29Vbi Vaccines Inc/bc : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
AQ
09/29VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine C..
CI
09/21Vbi Vaccines Inc/bc : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
AQ
09/21VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of it..
BU
09/21VBI Vaccines Inc. Announces Presentation of Physician-Initiated Compassionate Use Data ..
CI
09/15Vbi Vaccines Inc/bc : Entry into a Material Definitive Agreement, Creation of a Direct Fin..
AQ
09/15VBI Vaccines Inc. Enters into an Amendment to the Loan Agreement
CI
09/15VBI Vaccines Secures $100 Million Loan From K2 HealthVentures; VBI Shares Rise
MT
More news
Analyst Recommendations on VBI VACCINES INC.
More recommendations
Financials (USD)
Sales 2022 3,92 M - -
Net income 2022 -98,1 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,91x
Yield 2022 -
Capitalization 182 M 182 M -
Capi. / Sales 2022 46,5x
Capi. / Sales 2023 9,06x
Nbr of Employees 152
Free-Float 79,2%
Chart VBI VACCINES INC.
Duration : Period :
VBI Vaccines Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VBI VACCINES INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,71 $
Average target price 6,00 $
Spread / Average Target 750%
EPS Revisions
Managers and Directors
Jeffrey R. Baxter President, Chief Executive Officer & Director
Christopher McNulty CFO, Director & Head-Business Development
Steven H. Gillis Chairman
David Evander Anderson Chief Scientific Officer
Francisco Diaz-Mitoma Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
VBI VACCINES INC.-69.84%188
MODERNA, INC.-53.44%46 189
LONZA GROUP AG-38.51%35 456
IQVIA HOLDINGS INC.-35.80%33 872
ALNYLAM PHARMACEUTICALS, INC.23.48%25 132
SEAGEN INC.-11.49%25 028